JP6117208B2 - c−kitキナーゼインヒビターとしての化合物及び組成物 - Google Patents

c−kitキナーゼインヒビターとしての化合物及び組成物 Download PDF

Info

Publication number
JP6117208B2
JP6117208B2 JP2014528513A JP2014528513A JP6117208B2 JP 6117208 B2 JP6117208 B2 JP 6117208B2 JP 2014528513 A JP2014528513 A JP 2014528513A JP 2014528513 A JP2014528513 A JP 2014528513A JP 6117208 B2 JP6117208 B2 JP 6117208B2
Authority
JP
Japan
Prior art keywords
oxadiazol
pyridine
imidazo
carboxamide
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014528513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525444A (ja
JP2014525444A5 (enExample
Inventor
イエ,ヴィンス
リー,シャオリン
リュー,シャオドン
ローレン,ジョン
モルテーニ,ヴァレンチナ
ナバッカ,ジュリエット
グエン,バオ
マイケル ジェームス ペトラッシ,ハンク
マイケル ジェームス ペトラッシ,ハンク
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014525444A publication Critical patent/JP2014525444A/ja
Publication of JP2014525444A5 publication Critical patent/JP2014525444A5/ja
Application granted granted Critical
Publication of JP6117208B2 publication Critical patent/JP6117208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014528513A 2011-09-01 2012-08-28 c−kitキナーゼインヒビターとしての化合物及び組成物 Active JP6117208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
US61/530,028 2011-09-01
PCT/US2012/052621 WO2013033070A1 (en) 2011-09-01 2012-08-28 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
JP2014525444A JP2014525444A (ja) 2014-09-29
JP2014525444A5 JP2014525444A5 (enExample) 2015-10-29
JP6117208B2 true JP6117208B2 (ja) 2017-04-19

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528513A Active JP6117208B2 (ja) 2011-09-01 2012-08-28 c−kitキナーゼインヒビターとしての化合物及び組成物

Country Status (42)

Country Link
US (1) US9199981B2 (enExample)
EP (1) EP2751102B1 (enExample)
JP (1) JP6117208B2 (enExample)
KR (1) KR101959590B1 (enExample)
CN (1) CN103764653B (enExample)
AP (1) AP2014007494A0 (enExample)
AR (1) AR087752A1 (enExample)
AU (1) AU2012300248B2 (enExample)
BR (1) BR112014004504B1 (enExample)
CA (1) CA2845159C (enExample)
CL (1) CL2014000494A1 (enExample)
CO (1) CO6900140A2 (enExample)
CR (1) CR20140106A (enExample)
CU (1) CU20140023A7 (enExample)
CY (1) CY1121695T1 (enExample)
DK (1) DK2751102T3 (enExample)
EA (1) EA024293B1 (enExample)
ES (1) ES2732671T3 (enExample)
GT (1) GT201400036A (enExample)
HR (1) HRP20191140T1 (enExample)
HU (1) HUE044373T2 (enExample)
IL (1) IL231226A (enExample)
JO (1) JOP20120246B1 (enExample)
LT (1) LT2751102T (enExample)
MA (1) MA35459B1 (enExample)
ME (1) ME03395B (enExample)
MX (1) MX342329B (enExample)
MY (1) MY167245A (enExample)
PE (1) PE20141033A1 (enExample)
PH (1) PH12014500351B1 (enExample)
PL (1) PL2751102T3 (enExample)
PT (1) PT2751102T (enExample)
RS (1) RS59025B1 (enExample)
SG (1) SG2014011050A (enExample)
SI (1) SI2751102T1 (enExample)
TN (1) TN2014000061A1 (enExample)
TR (1) TR201909189T4 (enExample)
TW (1) TWI543981B (enExample)
UA (1) UA110841C2 (enExample)
UY (1) UY34300A (enExample)
WO (1) WO2013033070A1 (enExample)
ZA (1) ZA201401113B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
WO2015082411A1 (de) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
TW202108581A (zh) * 2019-05-13 2021-03-01 瑞士商諾華公司 N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
CN114423758B (zh) 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の結晶質形態
TW202237096A (zh) 2020-11-19 2022-10-01 瑞士商諾華公司 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4626884A1 (en) 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
EP4630423A1 (en) * 2022-12-07 2025-10-15 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024124002A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
US20250042898A1 (en) * 2023-07-25 2025-02-06 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
CN122580315A (zh) * 2024-01-04 2026-08-14 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用
TW202613113A (zh) * 2024-06-11 2026-04-01 大陸商上海翰森生物醫藥科技有限公司 吡唑類衍生物抑制劑、其製備方法和應用
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2025261494A1 (zh) * 2024-06-21 2025-12-26 上海美悦生物科技发展有限公司 一种稠杂环化合物、其制备方法和用途
WO2026026755A1 (zh) * 2024-07-30 2026-02-05 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026032333A1 (zh) * 2024-08-06 2026-02-12 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026037418A1 (zh) * 2024-08-16 2026-02-19 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
CA2845785A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103930424A (zh) * 2011-09-01 2014-07-16 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US8569283B2 (en) * 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors

Also Published As

Publication number Publication date
GT201400036A (es) 2015-06-02
RS59025B1 (sr) 2019-08-30
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
LT2751102T (lt) 2019-07-10
BR112014004504A2 (pt) 2017-03-28
ES2732671T3 (es) 2019-11-25
KR101959590B1 (ko) 2019-03-18
SG2014011050A (en) 2014-08-28
WO2013033070A1 (en) 2013-03-07
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29
SI2751102T1 (sl) 2019-08-30
AR087752A1 (es) 2014-04-16
PL2751102T3 (pl) 2019-09-30
CO6900140A2 (es) 2014-03-20
ZA201401113B (en) 2015-10-28
CL2014000494A1 (es) 2014-09-05
DK2751102T3 (da) 2019-07-01
EA201490540A1 (ru) 2014-06-30
BR112014004504B1 (pt) 2022-03-22
PT2751102T (pt) 2019-07-10
PH12014500351B1 (en) 2019-04-03
AU2012300248B2 (en) 2015-08-27
MX342329B (es) 2016-09-26
US20130059846A1 (en) 2013-03-07
TWI543981B (zh) 2016-08-01
IL231226A (en) 2017-03-30
NZ621092A (en) 2016-06-24
MA35459B1 (fr) 2014-09-01
US9199981B2 (en) 2015-12-01
CR20140106A (es) 2014-05-02
CN103764653B (zh) 2015-12-02
TR201909189T4 (tr) 2019-07-22
CN103764653A (zh) 2014-04-30
JOP20120246B1 (ar) 2022-03-14
PE20141033A1 (es) 2014-08-30
HUE044373T2 (hu) 2019-10-28
ME03395B (me) 2020-01-20
MY167245A (en) 2018-08-14
TW201313716A (zh) 2013-04-01
CU20140023A7 (es) 2014-04-24
UA110841C2 (uk) 2016-02-25
CA2845159C (en) 2020-11-03
CY1121695T1 (el) 2020-07-31
UY34300A (es) 2013-04-05
CA2845159A1 (en) 2013-03-07
EP2751102B1 (en) 2019-03-27
AP2014007494A0 (en) 2014-03-31
AU2012300248A1 (en) 2014-04-17
PH12014500351A1 (en) 2014-04-07
EA024293B1 (ru) 2016-09-30
MX2014002482A (es) 2014-11-25
IL231226A0 (en) 2014-04-30
EP2751102A1 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
JP6134319B2 (ja) c−kitキナーゼインヒビターとしての化合物及び組成物
CA2845159C (en) Compounds and compositions as c-kit kinase inhibitors
JP2014525450A (ja) c−Kitキナーゼ阻害剤としての化合物および組成物
JP2014525447A (ja) c−Kitキナーゼ阻害剤としての化合物および組成物
JP2014525462A (ja) Pdgfrキナーゼ阻害剤としての化合物および組成物
HK1193820A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193820B (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821B (en) Compounds and compositions as c-kit kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170322

R150 Certificate of patent or registration of utility model

Ref document number: 6117208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250